AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17217710
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil 20 mg
Trial: 15565999
Drug: BID group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID group (0.5 g morning and evening)
Trial: 15565999
Drug: TID group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TID group (0.25 g in the morning and about midday, and 0.5 g in the evening)
Trial: 1389661
Drug: iohexol with
RxNorm normalized name: Iohexol
DrugBank: Iohexol (DB01362)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iohexol with NaCl (28 mmol/l)
Trial: 30098162
Drug: Medical or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical or surgical treatment of the study eye (SE)
Trial: 23736314
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg oral naltrexone (NTX)
Trial: 23736314
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg oral naltrexone (NTX)
Trial: 23736314
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg oral naltrexone (NTX)
Trial: 23736314
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral D-amphetamine (D-AMPH)
Trial: 23736314
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg oral D-amphetamine (D-AMPH)
Trial: 23736314
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg smoked cocaine (COC)
Trial: 23736314
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg smoked cocaine (COC)
Trial: 23736314
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg smoked cocaine (COC)
Trial: 23736314
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg smoked cocaine (COC)
Trial: 21871685
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin treatment (Group A)
Trial: 21871685
Drug: Conventional insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional insulin treatment (Group B)
Trial: 17098309
Drug: Intravenous boluses
RxNorm normalized name: phenylbutazone
DrugBank: Phenylbutazone (DB00812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous boluses of quinaprilat
Trial: 17098309
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of sodium nitroprusside
Trial: 11578760
Drug: D002 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D002 (50 mg/day)
Trial: 1859509
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 60 mg amitriptylinoxide
Trial: 1859509
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 60 mg amitriptylinoxide
Trial: 1859509
Drug: Overall tolerability
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall tolerability of both preparations
Trial: 24225379
Drug: Fluocortolone (FC)
RxNorm normalized name: fluocortolone
DrugBank: Fluocortolone (DB08971)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluocortolone (FC) 1 mg/kg for 5 days, followed by stepwise dose reduction
Trial: 21952668
Drug: MDMA 0
RxNorm normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA 0 mg (placebo)
Trial: 21952668
Drug: MDMA 25
RxNorm normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA 25 mg
Trial: 3140150
Drug: Veralipride (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veralipride (100 mg/day for 30 days)
Trial: 3140150
Drug: Naloxone infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone infusion (N = 5) after Veralipride administration
Trial: 29893223
Drug: Personalised hip
RxNorm normalized name: HIP
DrugBank: Heme iron polypeptide (DB11067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalised hip therapy
Trial: 28814431
Drug: Calprotectin after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calprotectin after 12 months of treatment
Trial: 20569725
Drug: Vernakalant (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vernakalant (3 mg/kg intravenous infusion for 10 minutes, followed by 2 mg/kg if needed)
Trial: 17996926
Drug: Cyclophosphamide‐doxorubicin‐cisplatin (CAP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide‐doxorubicin‐cisplatin (CAP) chemotherapy
Trial: 4054701
Drug: Cimetidine 200
RxNorm normalized name: cimetidine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 200 mg tds with meals
Trial: 4054701
Drug: Cimetidine 600
RxNorm normalized name: cimetidine 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 600 mg at bedtime
Trial: 4054701
Drug: Cimetidine 200
RxNorm normalized name: cimetidine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 200 mg tds with meals plus 400 mg at bedtime
Trial: 30114193
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of antibiotics
Trial: 30114193
Drug: Symptoms influence
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptoms influence on antibiotic use
Trial: 30114193
Drug: Income influence
RxNorm normalized name: Lincomed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Income influence on antibiotic receipt
Trial: 30114193
Drug: Determinants of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Determinants of antibiotic use
Trial: 1963130
Drug: Rate of
RxNorm normalized name: Citrate of Magnesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rate of patient enrollment in the Early Treatment Diabetic Retinopathy Study (ETDRS)
Trial: 1963130
Drug: Inactive patients
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive patients in the Early Treatment Diabetic Retinopathy Study (ETDRS)
Trial: 27650328
Drug: Montelukast (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (20 mg/day)
Trial: 26807640
Drug: DC-LOP (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DC-LOP (IV paclitaxel at 60 mg/m² followed by IV carboplatin at AUC 6 and IV pegylated liposomal doxorubicin at 30 mg/m²)
Trial: 26807640
Drug: GC-LOP (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GC-LOP (IV paclitaxel at 60 mg/m² followed by IV gemcitabine at 1000 mg/m²)
Trial: 21142292
Drug: Intravenous microdose
RxNorm normalized name: LANCET,MICRODOT SAFETY 28G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous microdose of verapamil [0.05 mg] (period 1)
Trial: 21142292
Drug: Intravenous microdose
RxNorm normalized name: LANCET,MICRODOT SAFETY 28G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous microdose of verapamil [0.05 mg] administered concomitantly with an oral therapeutic dose [80 mg] (period 2)
Trial: 19074961
Drug: Repeated dose
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated dose of antenatal betamethasone
Trial: 16773465
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid mixture (108 g) given orally to cirrhotics
Trial: 11181660
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy (5 years of tamoxifen, polychemotherapy including cyclophosphamide/methotrexate/fluorouracil-like regimens, anthracycline-based therapy, or therapy based on both an anthracycline and a taxane)
Trial: 27225722
Drug: Oral L-carnitine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral L-carnitine, 1 g/L for 3 months
Trial: 25140957
Drug: GS-5806 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS-5806 (50 mg first dose, then 25 mg daily for 4 days)
Trial: 21733370
Drug: estradiol and
RxNorm normalized name: Estradiol and Norgestimate Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: estradiol and drospirenone tablets (Angeliq)
Trial: 20397455
Drug: Acupuncture and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture and herbal medicine
Trial: 12571165
Drug: Metformin for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin for 6 months followed by clomiphene citrate
Trial: 12571165
Drug: Cost-effective analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost-effective analysis for medications per pregnancy in group I
Trial: 10920060
Drug: Light to
RxNorm normalized name: MINERAL OIL,LIGHT TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light to moderate alcohol consumption (rarely/never, monthly, weekly, daily) among nondiabetic men
Trial: 10920060
Drug: Light to
RxNorm normalized name: MINERAL OIL,LIGHT TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light to moderate alcohol consumption (rarely/never, monthly, weekly, daily) among diabetic men
Trial: 1566986
Drug: Intravenous tubocurarine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tubocurarine 0.05 mg.kg‐1
Trial: 1566986
Drug: Intravenous chlorpromazine
RxNorm normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous chlorpromazine 0.1 mg.kg‐1
Trial: 1566986
Drug: Alphatocopherol (vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alphatocopherol (vitamin E) 600 mg in three divided doses orally
Trial: 1566986
Drug: Aspirin 600
RxNorm normalized name: aspirin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 600 mg orally
Trial: 1566986
Drug: Intravenous calcium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous calcium chloride 5 mg.kg‐1
Trial: 30986285
Drug: Computer-assisted implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-assisted implant planning based on three-dimensional (3D) computer-tomography (test group 1, n = 24)
Trial: 30986285
Drug: Computer-assisted implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-assisted implant planning based on three-dimensional (3D) computer-tomography (test group 2, n = 23)
Trial: 30986285
Drug: Conventional two-dimensional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional two-dimensional radiograph and free-hand implant placement (control, n = 26)
Trial: 26864301
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment of fractional 1550-nm ytterbium/erbium fiber laser and 0.1% tacrolimus ointment
Trial: 15213039
Drug: Lutein supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein supplement in oil (LS treatment, 1.7 mg lutein/d)
Trial: 15213039
Drug: Yellow carrots
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yellow carrots (YC treatment, 1.7 mg lutein/d)
Trial: 15213039
Drug: White carrots
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White carrots (WC treatment, 0 mg lutein/d)
Trial: 15213039
Drug: Yellow carrots
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yellow carrots (YC treatment)
Trial: 15213039
Drug: Lutein supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein supplement in oil (LS treatment)
Trial: 11448369
Drug: Venlafaxine hydrochloride
RxNorm normalized name: Venlafaxine Hydrochloride
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venlafaxine hydrochloride (37.5 mg twice-daily)
Trial: 9539918
Drug: Griseofulvin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Griseofulvin (10 mg/kg/day for 8 weeks)
Trial: 9539918
Drug: Terbinafine (62.5‐250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine (62.5‐250 mg/day for 4 weeks)
Trial: 8024798
Drug: Topical all-trans
RxNorm normalized name: all-trans-retinol
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical all-trans retinoic acid gel (Aberel)
Trial: 8024798
Drug: Salicylic acid
RxNorm normalized name: Salicylic Acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salicylic acid gel
Trial: 2478341
Drug: Chlormadinone acetate
RxNorm normalized name: Chlormadinone acetate
DrugBank: Chlormadinone acetate (DB15903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlormadinone acetate (CMA), 5 mg/day
Trial: 2478341
Drug: Previous study
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Previous study with 50 mg/day CMA
Trial: 7375
Drug: bromazepam (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bromazepam (9 mg)
Trial: 29947134
Drug: Bakuchiol 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bakuchiol 0.5% cream applied twice daily
Trial: 29947134
Drug: Retinol 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retinol 0.5% cream applied daily
Trial: 28327054
Drug: Low frequency
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low frequency (LF) rTMS + physical therapy (PT)
Trial: 28327054
Drug: Low frequency
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low frequency (LF) rTMS + NMES + physical therapy (PT)
Trial: 26126419
Drug: Cognitive Adaptation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Adaptation Training (CAT) weekly for 9 months; monthly thereafter
Trial: 16507179
Drug: Midazolam (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (administered in small, divided doses over 4-5 min until Wilson sedation score reached three)
Trial: 12173139
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A supplementation (3 mg retinol equivalent)
Trial: 7582385
Drug: Cetirizine 5
RxNorm normalized name: cetirizine 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 5 mg (0.32 +/- 0.07 mg.kg‐1) as a 10 mg.ml‐1 solution
Trial: 350498
Drug: Methylcysteine hydrochloride
RxNorm normalized name: Methylcysteine hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylcysteine hydrochloride (1200 mg daily in Week 1, 800 mg daily in Week 2, then 600 mg daily)
Trial: 350498
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical tablets, same regimen)
Trial: 28629872
Drug: Sevoflurane administered
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane administered at 1 minimal alveolar concentration for 5 minutes after being weaned from CPB (group SEV)
Trial: 28629872
Drug: Intravenous anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous anesthesia maintained (group CTRL)
Trial: 23412700
Drug: Camostat (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camostat (1.6 mg dose group)
Trial: 23412700
Drug: Camostat (estimated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camostat (estimated dose of 18 μg/mL)
Trial: 11394515
Drug: 20 microg
RxNorm normalized name: Calcifediol 20 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 microg fentanyl (0.4 ml)
Trial: 11394515
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 0.9% (0.4 ml)
Trial: 9972118
Drug: Sub-antimicrobial-dose doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sub-antimicrobial-dose doxycycline (SDD) 20 mg BID
Trial: 8071758
Drug: Intramuscular vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular vitamin A supplementation
Trial: 10933649
Drug: Erythromycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (250 mg every 6 h for 7 days)
Trial: 3179171
Drug: Phenytoin sodium
RxNorm normalized name: Phenytoin Sodium
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenytoin sodium (400 mg single oral dose)
Trial: 5309085
Drug: Two different
RxNorm normalized name: IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS ERBB2 (EPIDERMAL GROWTH FACTOR RECEPTOR 2, RECEPTOR TYROSINEPROTEIN KINASE ERBB-2, EGFR2, HER2, HER-2, P185C-ERBB2, NEU, CD340)), HUMANIZED MONOCLONAL ANTIBODY, BIPARATOPIC (TARGETING TWO DIFFERENT NON-OVERLAPP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two different vaccines
Trial: 31443102
Drug: 1.8 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 × 10^10 CFU B. infantis EVC001 daily for 21 days
Trial: 28421383
Drug: Guanfacine XR
RxNorm normalized name: guanfacine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine XR 1 mg orally on Day 1, followed by 1 mg (Days 4-8), 2 mg (Days 9-13), 3 mg (Days 14-18), and 4 mg (Days 19-23) once daily
Trial: 25966824
Drug: Individualized, formula-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized, formula-based dosing of Genotropin®
Trial: 25966824
Drug: Standard weight-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard weight-based dosing of Genotropin®
Trial: 24088130
Drug: Genotype-guided dosing
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype-guided dosing (genetic plus clinical information)
Trial: 19371312
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol (0.2 mg)
Trial: 16877722
Drug: Chronomodulated infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronomodulated infusion of fluorouracil, leucovorin, and oxaliplatin for 4 days (chronoFLO4)
Trial: 16877722
Drug: Chronomodulated infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronomodulated infusion (chronoFLO4) in women
Trial: 16877722
Drug: Chronomodulated infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronomodulated infusion (chronoFLO4) in men
Trial: 10902785
Drug: QUICKI (1/[log(I(0))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QUICKI (1/[log(I(0)) + log(G(0))])
Trial: 9076577
Drug: Calcitriol treatment
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcitriol treatment
Trial: 9076577
Drug: Before calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Before calcitriol treatment
Trial: 8222495
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg twice a day for 2 weeks after 1 week of placebo or indomethacin
Trial: 8222495
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg twice a day for 2 weeks after 1 week of placebo or indomethacin
Trial: 8222495
Drug: Indomethacin 50
RxNorm normalized name: indomethacin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 50 mg twice a day for 3 weeks
Trial: 18672472
Drug: Fampridine 10
RxNorm normalized name: dalfampridine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fampridine 10 mg twice daily
Trial: 18672472
Drug: Fampridine 15
RxNorm normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fampridine 15 mg twice daily
Trial: 18672472
Drug: Fampridine 20
RxNorm normalized name: famotidine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fampridine 20 mg twice daily
Trial: 15906951
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg conjugated equine estrogen (CEE) (n=139)
Trial: 15906951
Drug: CEE plus
RxNorm normalized name: Ecee Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE plus 5 mg medroxyprogesterone acetate (MPA) (n=97)
Trial: 15906951
Drug: CEE plus
RxNorm normalized name: Ecee Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE plus 10 mg MPA (n=109)
Trial: 12526069
Drug: Azithromycin 10
RxNorm normalized name: azithromycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 10 mg/kg/day for 3 days
Trial: 12888586
Drug: Co-amoxiclav 45
RxNorm normalized name: CO
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-amoxiclav 45 mg/kg/day for 10 days
Trial: 10531771
Drug: Tenoxicam 20
RxNorm normalized name: tenoxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam 20 mg i.v.
Trial: 9753705
Drug: Hyoscine N-butylbromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine N-butylbromide 20 mg i.v.
Trial: 7910470
Drug: Alprazolam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (1 mg) vs Suriclone (0.4 mg)
Trial: 3111101
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose dexamethasone
Trial: 3111101
Drug: Double doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double doses of dexamethasone